DiaMedica Therapeutics
Filed with the SEC on · accession 0001437749-26-036600
DMAC filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -3.4% by the first close after the filing.
DiaMedica Therapeutics announced its condensed consolidated financial results for the quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.
Close before
$9.66
Nov 11, 2026
First close after
-3.42%
$9.33
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for DMAC, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for DMAC?
Click hereDMAC filed a 8-K (SEC filing). DiaMedica Therapeutics announced its condensed consolidated financial results for the quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
DMAC closed at $9.66 before the filing and $9.33 on Nov 12, 2026 (-3.42%).
Get alerts when DMAC files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days